• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

作者信息

Woo J, Cheung W, Chan R, Chan H S, Cheng A, Chan K

机构信息

Dept. of Medicine, The Chinese University of Hong Kong.

出版信息

Clin Biochem. 1996 Apr;29(2):175-7. doi: 10.1016/0009-9120(95)02024-1.

DOI:10.1016/0009-9120(95)02024-1
PMID:8601328
Abstract
摘要

相似文献

1
In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.异烟肼、利福平及吡嗪酰胺与全血、白蛋白和α-1-酸性糖蛋白的体外蛋白质结合特性
Clin Biochem. 1996 Apr;29(2):175-7. doi: 10.1016/0009-9120(95)02024-1.
2
Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis.采用高效液相色谱法测定肺结核患者人血浆中吡嗪酰胺、异烟肼、乙酰异烟肼和利福平的含量。
J Sep Sci. 2021 Jan;44(2):521-529. doi: 10.1002/jssc.202000672. Epub 2020 Dec 10.
3
Comprehensive assay for pyrazinamide, rifampicin and isoniazid with its hydrazine metabolites in human plasma by column liquid chromatography.采用柱液相色谱法对人血浆中吡嗪酰胺、利福平及其肼类代谢物进行综合测定。
J Chromatogr B Biomed Appl. 1994 Aug 19;658(2):391-6. doi: 10.1016/0378-4347(94)00230-4.
4
Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.固定剂量复方胶囊中利福平、异烟肼和吡嗪酰胺的生物利用度。
Int J Tuberc Lung Dis. 1998 Oct;2(10):824-30.
5
Simultaneous determination of isoniazid, pyrazinamide, rifampicin and acetylisoniazid in human plasma by high-performance liquid chromatography.高效液相色谱法同时测定人血浆中的异烟肼、吡嗪酰胺、利福平和乙酰异烟肼。
Anal Sci. 2010;26(11):1133-8. doi: 10.2116/analsci.26.1133.
6
LC-QToF-MS method for quantification of ethambutol, isoniazid, pyrazinamide and rifampicin in human plasma and its application.液相色谱-四极杆飞行时间质谱法测定人血浆中乙胺丁醇、异烟肼、吡嗪酰胺和利福平及其应用
Biomed Chromatogr. 2020 May;34(5):e4812. doi: 10.1002/bmc.4812. Epub 2020 Mar 2.
7
Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.利福平、异烟肼和吡嗪酰胺在四种药物固定剂量组合与相同剂量水平的单独制剂中的相对生物利用度。
Int J Pharm. 2004 May 19;276(1-2):41-9. doi: 10.1016/j.ijpharm.2004.02.019.
8
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.利福平、异烟肼、吡嗪酰胺固定剂量复方制剂（与利福平、异烟肼、吡嗪酰胺和乙胺丁醇单独制剂相比）中利福平、异烟肼和吡嗪酰胺的生物等效性评估。
Int J Clin Pharmacol Ther. 2002 Oct;40(10):474-81. doi: 10.5414/cpp40474.
9
Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.异烟肼、利福平及吡嗪酰胺（游离组合或固定三联制剂）在间歇抗结核化疗中的生物利用度。
Monaldi Arch Chest Dis. 1993;48(3):205-9.
10
Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.血浆中利福平、异烟肼和吡嗪酰胺同时萃取后用高效液相色谱法测定。
Int J Tuberc Lung Dis. 1999 Nov;3(11 Suppl 3):S325-8; discussion S351-2.

引用本文的文献

1
The synergistic effect of the combination of polymyxin B and rifampicin in a murine neutropenic thigh infection model with E. coli and K. pneumoniae.多粘菌素B与利福平联合应用在小鼠中性粒细胞减少大腿感染大肠杆菌和肺炎克雷伯菌模型中的协同作用。
J Antimicrob Chemother. 2025 May 2;80(5):1248-1255. doi: 10.1093/jac/dkaf056.
2
Mechanistic Static Model based Prediction of Transporter Substrate Drug-Drug Interactions Utilizing Atorvastatin and Rifampicin.基于机制静态模型的阿托伐他汀和利福平预测药物转运体底物药物相互作用。
Pharm Res. 2023 Dec;40(12):3025-3042. doi: 10.1007/s11095-023-03613-x. Epub 2023 Oct 11.
3
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs.
抗结核药物 2a 期首次人体疗效研究的转化预测。
Eur Respir J. 2023 Aug 31;62(2). doi: 10.1183/13993003.00165-2023. Print 2023 Aug.
4
Analysis of influencing factors on the plasma concentration of first-line anti-tuberculosis drugs-a single-center retrospective cohort study.一线抗结核药物血浆浓度的影响因素分析——一项单中心回顾性队列研究
Ann Transl Med. 2022 Apr;10(8):461. doi: 10.21037/atm-22-1341.
5
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection.利福平在堪萨斯分枝杆菌感染中空纤维模型中的药代动力学/药效学。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0232021. doi: 10.1128/aac.02320-21. Epub 2022 Mar 22.
6
Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis.越南结核性脑膜炎患儿抗结核药物的群体药代动力学特性
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.00487-20.
7
Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.利福平血浆蛋白结合在结核病患者治疗中的临床意义
Clin Pharmacokinet. 2019 Dec;58(12):1511-1515. doi: 10.1007/s40262-019-00800-1.
8
Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.利福平在人类结核病中的临床药代动力学和药效学。
Clin Pharmacokinet. 2019 Sep;58(9):1103-1129. doi: 10.1007/s40262-019-00764-2.
9
Noninvasive C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis.非侵入性 C-利福平正电子发射断层扫描显示结核性脑膜炎中的药物生物分布。
Sci Transl Med. 2018 Dec 5;10(470). doi: 10.1126/scitranslmed.aau0965.
10
HPMA-PLGA Based Nanoparticles for Effective In Vitro Delivery of Rifampicin.基于 HPMA-PLGA 的纳米粒用于利福平的有效体外递送。
Pharm Res. 2018 Dec 3;36(1):19. doi: 10.1007/s11095-018-2543-x.